Would Shareholders Who Purchased Bionano Genomics'(NASDAQ:BNGO) Stock Year Be Happy With The Share price Today?
NASDAQ:BNGO) is up 81% in the last quarter. But that doesn’t change the fact that the returns over the last year have been disappointing. Like a receding glacier in a warming world, the share price has melted 57% in that period. So the bounce should be viewed in that context. It may be that the fall was an overreaction.” data-reactid=”28″>It is a pleasure to report that the Bionano Genomics, Inc. (NASDAQ:BNGO) is up 81% in the last quarter. But that doesn’t change the fact that the returns over the last year have been disappointing. Like a receding glacier in a warming world, the share price has melted 57% in that period. So the bounce should be viewed in that context. It may be that the fall was an overreaction.
Check out our latest analysis for Bionano Genomics ” data-reactid=”29″>Check out our latest analysis for Bionano Genomics
Given that Bionano Genomics didn’t make a profit in the last twelve months, we’ll focus on revenue growth to form a quick view of its business development. Generally speaking, companies without profits are expected to grow revenue every year, and at a good clip. That’s because it’s hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.
In just one year Bionano Genomics saw its revenue fall by 23%. That looks pretty grim, at a glance. The share price drop of 57% is understandable given the company doesn’t have profits to boast of. Fingers crossed this is the low ebb for the stock. We don’t generally like to own companies with falling revenues and no profits, so we’re pretty cautious of this one, at the moment.
You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).
report on how its financial position has changed over time.” data-reactid=”49″>Balance sheet strength is crucial. It might be well worthwhile taking a look at our free report on how its financial position has changed over time.
A Different Perspective
Bionano Genomics is showing 5 warning signs in our investment analysis , and 2 of those can’t be ignored…” data-reactid=”51″>Given that the market gained 21% in the last year, Bionano Genomics shareholders might be miffed that they lost 57%. However, keep in mind that even the best stocks will sometimes underperform the market over a twelve month period. It’s great to see a nice little 81% rebound in the last three months. This could just be a bounce because the selling was too aggressive, but fingers crossed it’s the start of a new trend. It’s always interesting to track share price performance over the longer term. But to understand Bionano Genomics better, we need to consider many other factors. Even so, be aware that Bionano Genomics is showing 5 warning signs in our investment analysis , and 2 of those can’t be ignored…
list of growing companies with considerable, recent, insider buying.” data-reactid=”52″>We will like Bionano Genomics better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.
Get in touch with us directly. Alternatively, email [email protected].” data-reactid=”54″>This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected].
